Horizon Therapeutics plc
https://www.horizontherapeutics.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Horizon Therapeutics plc
Genmab's Growth Strategy: Embracing A ‘Super Rational, Data-Driven' Mindset
The “Genmab sauce” will be crucial as the Danish biotech loads up on late-stage assets, grows its capabilities and expands into immunology and inflammation.
Taking On Vyvgart In Myasthenia Gravis
Argenx has aggressive market expansion plans for Vyvgart. It also has several late-stage challengers in what is becoming a dynamic market.
Amgen Lays Out Plans For Rare Disease Portfolio Growth
Amgen detailed plans for increasing sales of drugs acquired in its Horizon transaction and outlined growth opportunities in its R&D pipeline during a rare disease showcase.
Genmab On The Hunt For Late-Stage Assets
The Danish biotech has dipped its toe into co-commercialization recently and is seeking more candidates that are getting closer to the market.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Bio-Technology General Corporation
- Crealta Holdings LLC
- Crealta Pharmaceuticals
- Curzion Pharmaceuticals, Inc.
- Encode Pharmaceuticals, Inc.
- Horizon Pharma plc
- Hyperion Therapeutics, Inc. (Andromeda Biotech Ltd)
- Nitec Pharma AG
- Raptor Pharmaceutical Corp.
- River Vision Development Corp.
- Savient Pharmaceuticals, Inc. (SVNT)
- TorreyPines Therapeutics, Inc. (Neurogenetics Inc.)
- Vidara Therapeutics Inc
- Viela Bio, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice